Historical Valuation
United Therapeutics Corp (UTHR) is now in the Overvalued zone, suggesting that its current forward PE ratio of 17.48 is considered Overvalued compared with the five-year average of 12.40. The fair price of United Therapeutics Corp (UTHR) is between 341.34 to 430.20 according to relative valuation methord. Compared to the current price of 490.83 USD , United Therapeutics Corp is Overvalued By 14.09%.
Relative Value
Fair Zone
341.34-430.20
Current Price：490.83
14.09%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
United Therapeutics Corp (UTHR) has a current Price-to-Book (P/B) ratio of 3.23. Compared to its 3-year average P/B ratio of 2.27 , the current P/B ratio is approximately 42.36% higher. Relative to its 5-year average P/B ratio of 2.30, the current P/B ratio is about 40.73% higher. United Therapeutics Corp (UTHR) has a Forward Free Cash Flow (FCF) yield of approximately 5.25%. Compared to its 3-year average FCF yield of 6.51%, the current FCF yield is approximately -19.42% lower. Relative to its 5-year average FCF yield of 6.56% , the current FCF yield is about -19.98% lower.
P/B
Median3y
2.27
Median5y
2.30
FCF Yield
Median3y
6.51
Median5y
6.56
Competitors Valuation Multiple
AI Analysis for UTHR
The average P/S ratio for UTHR competitors is 35.95, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR.O) exhibits a P/S ratio of 6.38, which is -82.26% above the industry average. Given its robust revenue growth of 6.76%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for UTHR
1Y
3Y
5Y
Market capitalization of UTHR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of UTHR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is UTHR currently overvalued or undervalued?
United Therapeutics Corp (UTHR) is now in the Overvalued zone, suggesting that its current forward PE ratio of 17.48 is considered Overvalued compared with the five-year average of 12.40. The fair price of United Therapeutics Corp (UTHR) is between 341.34 to 430.20 according to relative valuation methord. Compared to the current price of 490.83 USD , United Therapeutics Corp is Overvalued By 14.09% .
What is United Therapeutics Corp (UTHR) fair value?
UTHR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of United Therapeutics Corp (UTHR) is between 341.34 to 430.20 according to relative valuation methord.
How does UTHR's valuation metrics compare to the industry average?
The average P/S ratio for UTHR's competitors is 35.95, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR) exhibits a P/S ratio of 6.38, which is -82.26% above the industry average. Given its robust revenue growth of 6.76%, this premium appears unsustainable.
What is the current P/B ratio for United Therapeutics Corp (UTHR) as of Jan 09 2026?
As of Jan 09 2026, United Therapeutics Corp (UTHR) has a P/B ratio of 3.23. This indicates that the market values UTHR at 3.23 times its book value.
What is the current FCF Yield for United Therapeutics Corp (UTHR) as of Jan 09 2026?
As of Jan 09 2026, United Therapeutics Corp (UTHR) has a FCF Yield of 5.25%. This means that for every dollar of United Therapeutics Corp’s market capitalization, the company generates 5.25 cents in free cash flow.
What is the current Forward P/E ratio for United Therapeutics Corp (UTHR) as of Jan 09 2026?
As of Jan 09 2026, United Therapeutics Corp (UTHR) has a Forward P/E ratio of 17.48. This means the market is willing to pay $17.48 for every dollar of United Therapeutics Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for United Therapeutics Corp (UTHR) as of Jan 09 2026?
As of Jan 09 2026, United Therapeutics Corp (UTHR) has a Forward P/S ratio of 6.38. This means the market is valuing UTHR at $6.38 for every dollar of expected revenue over the next 12 months.